Natural history of hypercholesterolemia in systemic lupus erythematosus

Journal of Rheumatology

Volumn 26, Issue 10, 1999, Pages 2137-2143

  Bruce, Ian N ^a   Urowitz, Murray B ^a,b   Gladman, Dafna D ^a   Hallett, David C ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Hypercholesterolemia; Systemic lupus erythematosus

Indexed keywords

CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGE OF ONSET; CHOLESTEROL; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0032867487     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408-15.
2. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventative practices. Medicine (Baltimore) 1992;71:291-302.
3. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14 Suppl 13:223-6.
4. Petri M, Perez-Gutthan S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
5. Hearth-Holmes M, Baethge BA, Broadwell L, Wolf RE. Dietary treatment of hyperlipidaemia in patients with systemic lupus erythematosus. J Rheumatol 1995;22:450-4.
6. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
7. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single centre. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-70.
8. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
9. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc, Series B 1972;34:187-220.
10. SAS Institute Inc. SAS/STAT Software: Changes and enhancements through release 6.12. Cary, NC: SAS Institute Inc.: 1997.
11. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81;3:515-26.
12. Wallace DJ, Metzger AL, Stetcher V, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of corticosteroids on lipids. Am J Med 1990;89:322-6.
13. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH. The lipid, lipoprotein and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993;20:661-5.
14. Rahman P, Gladman DD, Urowitz MB, et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroids. J Rheumatol 1999;26:325-30.
15. Petri M. Hydroxychloroquine: past, present and future. Lupus 1998;7:65-7.
16. Wallace DJ. Is hydroxychloroquine destined for a larger role in managing systemic lupus erythematosus? J Clin Rheumatol 1997;3:1-2.
17. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996;125:990-1000.